StemCells Inc  

(Public, NASDAQ:STEM)   Watch this stock  
Find more results for STEM
1.77
+0.05 (2.91%)
Jun 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.71 - 1.77
52 week 0.62 - 2.67
Open 1.75
Vol / Avg. 344,539.00/390,816.00
Mkt cap 68.83M
P/E     -
Div/yield     -
EPS -0.75
Shares 38.89M
Beta 0.42
Inst. own 7%
May 9, 2013
Q1 2013 StemCells, Inc. Earnings Conference Call - Webcast
Apr 17, 2013
StemCells, Inc. at 2013 Regen Med Investor Day - Webcast
Mar 21, 2013
Q4 and 2012 StemCells, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -2257.72% -2082.75%
Operating margin -2201.67% -1648.12%
EBITD margin - -1549.56%
Return on average assets -93.70% -102.90%
Return on average equity -212.76% -230.61%
Employees 49 -
Carbon Disclosure Rating - -

Address

Suite 140, 7707 Gateway Blvd
NEWARK, CA 94560
United States - Map
+1-510-4564000 (Phone)
+1-510-4564001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related tools and technologies for academia and industry. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies, and cells and related tools and technologies to enable stem cell-based research and drug discovery and development. The Company�s primary research and development efforts are focused on identifying and developing stem and progenitor cells as potential therapeutic agents. The Company has two therapeutic product development programs, including its CNS Program, which is developing applications for HuCNS-SC cells, its human neural stem cell product candidate, and its Liver Program, which is characterizing the Company�s human liver cells as a therapeutic product.

Officers and directors

John J. Schwartz Ph.D. Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Martin M. McGlynn President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Rodney K. B. Young Chief Financial Officer, Vice President - Finance and Administration
Age: 49
Bio & Compensation  - Reuters
Eliseo Oreste Salinas M.D. Executive Vice President, Head - Research and Development
Bio & Compensation  - Reuters
Ann Tsukamoto Ph.D. Executive Vice President - Scientific and Strategic Alliances
Bio & Compensation  - Reuters
Stewart Craig Ph.D. Senior Vice President - Development and Operations
Age: 50
Bio & Compensation  - Reuters
Kenneth Stratton J.D. General Counsel
Age: 43
Bio & Compensation  - Reuters
Irving L Weissman M.D. Director
Age: 72
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 53
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 53
Bio & Compensation  - Reuters